Frequencies

`[DataSet9]`

Statistics

		basal insulin	prandial insulin	SGLT2i	GLP-1RA	DPP-4i	Combinations
N	Valid	18	18	18	18	0	0
	Missing	0	0	0	0	18	18

Statistics

		patient gender	patient insurance type	metformin use	sulfonylurea use	meglitinide use
N	Valid	18	18	18	18	18
	Missing	0	0	0	0	0

Statistics

		TZD use	other insulin use
N	Valid	18	18
	Missing	0	0

Frequency Table

basal insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		1	5.6	5.6	5.6
	Basaglar	9	50.0	50.0	55.6
	Tresiba	8	44.4	44.4	100.0
	Total	18	100.0	100.0	

prandial insulin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		13	72.2	72.2	72.2
	Humalog	1	5.6	5.6	77.8
	Novolog	4	22.2	22.2	100.0
	Total	18	100.0	100.0	

SGLT2i

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid		13	72.2	72.2	72.2
	Farxiga	3	16.7	16.7	88.9
	Jardiance	2	11.1	11.1	100.0
	Total	18	100.0	100.0	

GLP-1RA

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ozempic	8	44.4	44.4	44.4
	Trulicity	9	50.0	50.0	94.4
	Victoza	1	5.6	5.6	100.0
	Total	18	100.0	100.0	

DPP-4i

		Frequency	Percent
Missing	System	18	100.0

Combinations

		Frequency	Percent
Missing	System	18	100.0

patient gender

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	female	14	77.8	77.8	77.8
	male	4	22.2	22.2	100.0
	Total	18	100.0	100.0	

patient insurance type

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Medicare part D	18	100.0	100.0	100.0

metformin use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	9	50.0	50.0	50.0
	Yes - both	9	50.0	50.0	100.0
	Total	18	100.0	100.0	

sulfonylurea use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	14	77.8	77.8	77.8
	Yes both baseline and 12 months	4	22.2	22.2	100.0
	Total	18	100.0	100.0	

meglitinide use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	18	100.0	100.0	100.0

TZD use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	No	18	100.0	100.0	100.0

other insulin use

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Yes baseline and 12 months	9	50.0	50.0	50.0
	Yes- baseline only	9	50.0	50.0	100.0
	Total	18	100.0	100.0	

T-Test

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	total # meds prior to PAP	12.94	18	3.842	.906
	total # meds 6 months after PAP	14.83	18	4.743	1.118
Pair 2	total # DM meds prior to PAP	2.06	18	.802	.189
	total # DM meds 6 months after PAP	2.94	18	.725	.171
Pair 3	baseline A/C ratio	124.653	15	178.0697	45.9774
	12 month A/C ratio	205.673	15	297.8448	76.9032
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1)	1.00	18	.686	.162
	# renal protective meds 12 months	2.00	18	.767	.181
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1)	1.39	18	.502	.118
	# CV protective meds 12 months	2.33	18	.686	.162
Pair 6	# hypoglycemia potential meds baseline	1.44	18	.616	.145
	# hypoglycemia potential meds 12 months	1.28	18	.752	.177

Paired Samples Correlations

		N	Correlation	Significance	
				One-Sided p	Two-Sided p
Pair 1	total # meds prior to PAP & total # meds 6 months after PAP	18	.932	<.001	<.001
Pair 2	total # DM meds prior to PAP & total # DM meds 6 months after PAP	18	.410	.046	.091
Pair 3	baseline A/C ratio & 12 month A/C ratio	15	.404	.068	.135
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) & # renal protective meds 12 months	18	.894	<.001	<.001
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) & # CV protective meds 12 months	18	.627	.003	.005
Pair 6	# hypoglycemia potential meds baseline & # hypoglycemia potential meds 12 months	18	.734	<.001	<.001

Paired Samples Test

		Paired Differences			
					95% Confidence Interval of the ...
		Mean	Std. Deviation	Std. Error Mean	Lower
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	-1.889	1.811	.427	-2.790
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	-.889	.832	.196	-1.303
Pair 3	baseline A/C ratio - 12 month A/C ratio	-81.0200	278.4827	71.9039	-235.2386
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	-1.000	.343	.081	-1.171
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	-.944	.539	.127	-1.213

Paired Samples Test

		Paired ...			Significance	
		95% Confidence Interval of the ...				
		Upper	t	df	One-Sided p	Two-Sided p
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	-.988	-4.424	17	<.001	<.001
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	-.475	-4.531	17	<.001	<.001
Pair 3	baseline A/C ratio - 12 month A/C ratio	73.1986	-1.127	14	.139	.279
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	-.829	-12.369	17	<.001	<.001
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	-.676	-7.430	17	<.001	<.001

Paired Samples Test

		Paired Differences			
					95% Confidence Interval of the ...
		Mean	Std. Deviation	Std. Error Mean	Lower
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	.167	.514	.121	-.089

Paired Samples Test

		Paired ...			Significance	
		95% Confidence Interval of the ...				
		Upper	t	df	One-Sided p	Two-Sided p
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	.423	1.374	17	.094	.187

Paired Samples Effect Sizes

					95% ...
			Standardizer[a]	Point Estimate	Lower
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	Cohen's d	1.811	-1.043	-1.611
		Hedges' correction	1.896	-.996	-1.539
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	Cohen's d	.832	-1.068	-1.641
		Hedges' correction	.871	-1.020	-1.568
Pair 3	baseline A/C ratio - 12 month A/C ratio	Cohen's d	278.4827	-.291	-.803
		Hedges' correction	294.6010	-.275	-.759
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	Cohen's d	.343	-2.915	-3.983
		Hedges' correction	.359	-2.785	-3.804
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	Cohen's d	.539	-1.751	-2.486
		Hedges' correction	.565	-1.673	-2.374
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	Cohen's d	.514	.324	-.155
		Hedges' correction	.539	.309	-.148

Paired Samples Effect Sizes

			95% ...
			Upper
Pair 1	total # meds prior to PAP - total # meds 6 months after PAP	Cohen's d	-.455
		Hedges' correction	-.434
Pair 2	total # DM meds prior to PAP - total # DM meds 6 months after PAP	Cohen's d	-.475
		Hedges' correction	-.453
Pair 3	baseline A/C ratio - 12 month A/C ratio	Cohen's d	.231
		Hedges' correction	.219
Pair 4	# renal protective meds baseline (ACE, ARB, SGLT2, GLP1) - # renal protective meds 12 months	Cohen's d	-1.832
		Hedges' correction	-1.750
Pair 5	# CV protective meds baseline (statin, SGLT2, GLP1) - # CV protective meds 12 months	Cohen's d	-.997
		Hedges' correction	-.952
Pair 6	# hypoglycemia potential meds baseline - # hypoglycemia potential meds 12 months	Cohen's d	.794
		Hedges' correction	.758

a. The denominator used in estimating the effect sizes.
Cohen's d uses the sample standard deviation of the mean difference.
Hedges' correction uses the sample standard deviation of the mean difference, plus a correction factor.

Bayesian One-way Repeated Measures ANOVA

Case Processing Summary

	N	Percent
Included	16	88.9%
Excluded	2	11.1%
Total	18	100.0%

Descriptive Statistics of Within-Subject Factor Levels

Dependent Variables	Mean	Std. Deviation	N	Min	Max
baseline A1c	8.569	1.6040	16	6.0	11.7
6 month A1c	7.306	1.0767	16	6.1	9.5
12 month A1c	7.588	.9047	16	6.4	8.9

Bayesian Estimates of Group Means[a]

Dependent Variables	Mode	Posterior Mean	Variance	95% Credible Interval Lower Bound	95% Credible Interval Upper Bound
baseline A1c	8.569	8.569	.089	7.984	9.153
6 month A1c	7.306	7.306	.089	6.722	7.891
12 month A1c	7.588	7.588	.089	7.003	8.172

a. Posterior distribution was estimated based on the Bayesian Central Limit Theorem.

Bayesian One-way Repeated Measures ANOVA

Case Processing Summary

	N	Percent
Included	17	94.4%
Excluded	1	5.6%
Total	18	100.0%

Descriptive Statistics of Within-Subject Factor Levels

Dependent Variables	Mean	Std. Deviation	N	Min	Max
baseline weight (kg)	97.788	19.3254	17	72.1	140.6
6 month weight	95.712	20.5855	17	64.8	143.5
12 month weight	94.971	20.8243	17	68.4	142.4

Bayesian Estimates of Group Means[a]

	Posterior			95% Credible Interval	
Dependent Variables	Mode	Mean	Variance	Lower Bound	Upper Bound
baseline weight (kg)	97.788	97.788	22.715	88.447	107.130
6 month weight	95.712	95.712	22.715	86.370	105.053
12 month weight	94.971	94.971	22.715	85.629	104.312

a. Posterior distribution was estimated based on the Bayesian Central Limit Theorem.

Descriptives

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
# of patient assistance medications	18	2	4	2.50	.618
patient age	18	48	81	68.67	7.769
Valid N (listwise)	18				